News

In the Phase III PANORAMA-1 (PANobinostat ORAl in Multiple MyelomA) trial, the addition of LBH589 also led to clinically meaningful increases in complete and near complete response rates

In the study, lung fibrosis, as measured by quantitative high resolution computed tomography (HRCT), was reduced in a substantial portion of patients who received FG-3019. FG-3019 is a

Biotec is a provider of clinical trials and temperature controlled pharmaceutical services. The company said that the acquisition will help in expanding its presence in the UK/EU region

Zydelig is an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta, which plays a major role in the activation, proliferation and viability of B cells, a critical component of

The trial called DURATION-NEO-1 compared an investigational formulation of exenatide once-weekly suspension for autoinjection with twice-daily exenatide (Byetta) injection in these patients who had inadequate glycaemic control. About

GSK China Investment (GSKCI) offered money or property to non-government personnel in order to obtain improper commercial gains, and been found guilty of bribing non-government personnel. The company

Under the deal, Tramorgan has secured the exclusive marketing sales and distribution rights of Innovus’ topical consumer care product to increase penile sensitivity. The deal has an initial

The company said that the trial failed to meet its primary endpoint of non-inferiority; however, the results showed that HbA1c was reduced for patients on either regimen, to

The once-weekly subcutaneous injection, Trulicity is designed to improve glycemic control (blood sugar levels), along with diet and exercise, in these patients. Trulicity is not recommended as first-line